The AI in SaMD Trifecta: What FDA’s Latest Moves Mean for Your AI-Enabled Product Roadmap
Summary
FDA issued linked final and draft guidance (Dec 2024 and Jan 2025) establishing a framework for AI-enabled SaMD that centers on Predetermined Change Control Plans (PCCPs) and a Total Product Life Cycle (TPLC) approach. PCCPs must include a Description of Modifications, a Modification Protocol, and an Impact Assessment, letting companies implement authorized post-clearance changes if they document expected changes up front. The draft lifecycle guidance raises transparency expectations around data lineage, claim-backed performance, and subgroup analyses, and requires informing users when devices operate under an authorized PCCP. Product teams should create a Model Evolution Roadmap, strengthen data and validation infrastructure, and decide early whether a PCCP is needed to reduce future regulatory friction. Monitor finalization of the draft guidance and additional FDA communications, especially for generative, foundation, and multimodal models, and build flexibility into regulatory and technical plans.